Ayala Pharmaceuticals Inc (ADXS)

[fbg0316]

Unfortunately he's an example of a LTSH capitulating and selling out of frustration at the wrong time at such a low valuation. Stepping back and looking at the Phase 3 that has begun and the company for gearing up for Europe and stating they were looking for a commercialization deal, I think we're going to be in for a big surprise. Also, notice in the weeks before the Amgen deal, the stock was beaten down to the mid $7s like we have seen in the last week. It's accumulation going on in anticipation of a big deal catalyst coming soon. As James Salmon suggested, I wouldn't be surprised if we see a deal before the April 5 annual meeting.